Literature DB >> 12230001

Combining several screening tests: optimality of the risk score.

Martin W McIntosh1, Margaret Sullivan Pepe.   

Abstract

The development of biomarkers for cancer screening is an active area of research. While several biomarkers exist, none is sufficiently sensitive and specific on its own for population screening. It is likely that successful screening programs will require combinations of multiple markers. We consider how to combine multiple disease markers for optimal performance of a screening program. We show that the risk score, defined as the probability of disease given data on multiple markers, is the optimal function in the sense that the receiver operating characteristic (ROC) curve is maximized at every point. Arguments draw on the Neyman-Pearson lemma. This contrasts with the corresponding optimality result of classic decision theory, which is set in a Bayesian framework and is based on minimizing an expected loss function associated with decision errors. Ours is an optimality result defined from a strictly frequentist point of view and does not rely on the notion of associating costs with misclassifications. The implication for data analysis is that binary regression methods can be used to yield appropriate relative weightings of different biomarkers, at least in large samples. We propose some modifications to standard binary regression methods for application to the disease screening problem. A flexible biologically motivated simulation model for cancer biomarkers is presented and we evaluate our methods by application to it. An application to real data concerning two ovarian cancer biomarkers is also presented. Our results are equally relevant to the more general medical diagnostic testing problem, where results of multiple tests or predictors are combined to yield a composite diagnostic test. Moreover, our methods justify the development of clinical prediction scores based on binary regression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12230001     DOI: 10.1111/j.0006-341x.2002.00657.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  66 in total

1.  Homogeneity tests of clustered diagnostic markers with applications to the BioCycle Study.

Authors:  Liansheng Larry Tang; Aiyi Liu; Enrique F Schisterman; Xiao-Hua Zhou; Catherine Chun-Ling Liu
Journal:  Stat Med       Date:  2012-06-26       Impact factor: 2.373

2.  Next-generation stool DNA test accurately detects colorectal cancer and large adenomas.

Authors:  David A Ahlquist; Hongzhi Zou; Michael Domanico; Douglas W Mahoney; Tracy C Yab; William R Taylor; Malinda L Butz; Stephen N Thibodeau; Linda Rabeneck; Lawrence F Paszat; Kenneth W Kinzler; Bert Vogelstein; Niels Chr Bjerregaard; Søren Laurberg; Henrik Toft Sørensen; Barry M Berger; Graham P Lidgard
Journal:  Gastroenterology       Date:  2011-11-04       Impact factor: 22.682

3.  A serial risk score approach to disease classification that accounts for accuracy and cost.

Authors:  Dat Huynh; Oliver Laeyendecker; Ron Brookmeyer
Journal:  Biometrics       Date:  2014-08-25       Impact factor: 2.571

4.  Integrating the predictiveness of a marker with its performance as a classifier.

Authors:  Margaret S Pepe; Ziding Feng; Ying Huang; Gary Longton; Ross Prentice; Ian M Thompson; Yingye Zheng
Journal:  Am J Epidemiol       Date:  2007-11-02       Impact factor: 4.897

5.  Evaluating the ROC performance of markers for future events.

Authors:  Margaret S Pepe; Yingye Zheng; Yuying Jin; Ying Huang; Chirag R Parikh; Wayne C Levy
Journal:  Lifetime Data Anal       Date:  2007-12-07       Impact factor: 1.588

6.  Combining multiple biomarker models in logistic regression.

Authors:  Zheng Yuan; Debashis Ghosh
Journal:  Biometrics       Date:  2008-03-05       Impact factor: 2.571

7.  Using the optimal receiver operating characteristic curve to design a predictive genetic test, exemplified with type 2 diabetes.

Authors:  Qing Lu; Robert C Elston
Journal:  Am J Hum Genet       Date:  2008-03       Impact factor: 11.025

8.  Combining multiple biomarkers linearly to maximize the partial area under the ROC curve.

Authors:  Qingxiang Yan; Leonidas E Bantis; Janet L Stanford; Ziding Feng
Journal:  Stat Med       Date:  2017-10-30       Impact factor: 2.373

9.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

Authors:  M W McIntosh; C Drescher; B Karlan; N Scholler; N Urban; K E Hellstrom; I Hellstrom
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

10.  Landmark risk prediction of residual life for breast cancer survival.

Authors:  Layla Parast; Tianxi Cai
Journal:  Stat Med       Date:  2013-03-14       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.